Novo Nordisk A/S (NYSE:NVO) Trading 0.3% Higher

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shot up 0.3% during trading on Friday . The stock traded as high as $130.16 and last traded at $128.40. 3,656,540 shares were traded during mid-day trading, a decline of 39% from the average session volume of 5,949,096 shares. The stock had previously closed at $128.05.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent analyst reports. TD Cowen boosted their price target on Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an "outperform" rating in a research note on Monday, December 4th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price target for the company. UBS Group started coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a "neutral" rating on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $126.25.

Novo Nordisk A/S Trading Up 0.3 %

The company has a 50 day moving average of $122.18 and a two-hundred day moving average of $104.55. The stock has a market capitalization of $576.20 billion, a PE ratio of 47.47, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Sell-side analysts predict that Novo Nordisk A/S will post 3.35 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be issued a $0.664 dividend. The ex-dividend date of this dividend is Friday, March 22nd. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.17%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVO. Cornerstone Planning Group LLC purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth about $29,000. Tower Research Capital LLC TRC raised its holdings in Novo Nordisk A/S by 165.3% in the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company's stock valued at $32,000 after acquiring an additional 124 shares in the last quarter. CNB Bank purchased a new position in Novo Nordisk A/S in the fourth quarter worth approximately $26,000. Pacific Center for Financial Services grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Finally, Valued Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.